Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue

Prostate

Volumn 75, Issue 16, 2015, Pages 1941-1950

  Geybels, Milan S ^a,b   Zhao, Shanshan ^a,c   Wong, Chao Jen ^a   Bibikova, Marina ^d   Klotzle, Brandy ^d   Wu, Michael ^a   Ostrander, Elaine A ^e   Fan, Jian Bing ^d   Feng, Ziding ^f   Stanford, Janet L ^a,g  

^a USA   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d ILLUMINA INC   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

benign; DNA methylation; mRNA expression; prostate cancer; tumor

Indexed keywords

MESSENGER RNA;

ADULT; AOX1 GENE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC SCREENING; HIF3A GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT ACCURACY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; SCGB3A1 GENE; TISSUE SECTION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84944442183     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23093     Document Type: Article

References (48)

1. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
2. Jones PA, Baylin SB,. The epigenomics of cancer. Cell 2007; 128: 683-692.
3. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF,. Epigenetics in prostate cancer: Biologic and clinical relevance. Eur Urol 2011; 60: 753-766.
4. Lou S, Lee HM, Qin H, Li JW, Gao Z, Liu X, Chan LL, Kl Lam V, Wang Y, Lok S, Wang J, Ma RC, Tsui SK, Chan JC, Chan TF, Yip KY,. Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation. Genome Biol 2014; 15: 408.
5. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G,. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014; 26: 577-590.
6. McKee TC, Tricoli JV,. Epigenetics of prostate cancer. Methods Mol Biol 2015; 1238: 217-234.
7. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W,. The epigenetic promise for prostate cancer diagnosis. Prostate 2012; 72: 1248-1261.
8. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI,. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014; 192: 1081-1087.
9. Devaney JM, Wang S, Funda S, Long J, Taghipour DJ, Tbaishat R, Furbert-Harris P, Ittmann M, Kwabi-Addo B,. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis 2013; 16: 292-300.
10. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM,. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011; 21: 1028-1041.
11. Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, Lindberg J, Egevad L, Gronberg H, Isaacs WB, Xu J,. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS ONE 2012; 7: e48455.
12. Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T, Zhu Y,. Genome-wide methylation analysis identifies involvement of TNF-alpha mediated cancer pathways in prostate cancer. Cancer Lett 2011; 302: 47-53.
13. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G,. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011; 21: 1017-1027.
14. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B,. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS ONE 2009; 4: e4830.
15. Luo JH, Ding Y, Chen R, Michalopoulos G, Nelson J, Tseng G, Yu YP,. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol 2013; 182: 2028-2036.
16. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV,. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012; 18: 2882-2895.
17. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL,. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250-260.
18. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK,. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 881-886.
19. Stott-Miller M, Zhao S, Wright JL, Kolb S, Bibikova M, Klotzle B, Ostrander EA, Fan JB, Feng Z, Stanford JL,. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2014; 23: 1331-1339.
20. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA,. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 2014; 30: 1363-1369.
21. Maksimovic J, Gordon L, Oshlack A,. SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol 2012; 13: R44.
22. Johnson WE, Li C, Rabinovic A,. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
23. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM,. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010; 11: 587.
24. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK,. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
25. Storey JD, Tibshirani R,. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.
26. Hansen K., IlluminaHumanMethylation450kanno.ilmn12.hg19: Annotation for illumina's 450k methylation arrays. R package version 0.2. 1.
27. Butcher LM, Beck S,. Probe lasso: A novel method to rope in differentially methylated regions with 450K DNA methylation data. Methods 2015; 72: 21-28.
28. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Hoyer S, Orntoft TF, Sorensen KD,. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013; 31: 3250-3258.
29. Borno ST, Fischer A, Kerick M, Falth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Rohr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sultmann H, Lehrach H, Schweiger MR,. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2012; 2: 1024-1035.
30. Garattini E, Terao M,. The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metabol Toxicol 2012; 8: 487-503.
31. Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R, Group UKPI, Warren AY, Tavare S, Neal DE, Lynch AG,. HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocr Relat Cancer 2015; 22: 131-144.
32. van der Meer LT, Jansen JH, van der Reijden BA,. Gfi1 and Gfi1b: Key regulators of hematopoiesis. Leukemia 2010; 24: 1834-1843.
33. Adams EJ, Luoma AM,. The adaptable major histocompatibility mplex (MHC) fold: Structure and function of classical and MHC class I-like molecules. Ann Rev Immunol 2013; 31: 529-561.
34. Tham C, Chew M, Soong R, Lim J, Ang M, Tang C, Zhao Y, Ong SY, Liu Y,. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer 2014; 120: 3131-3141.
35. Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glockner SC, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, Baylin SB, Herman JG, Brock MV,. Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res 2014; 20: 1856-1864.
36. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K,. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004; 2: 489-494.
37. Dai D, Dong XH, Cheng ST, Zhu G, Guo XL,. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: A meta-analysis. Tumour Biol 2014; 35: 8209-8216.
38. Ho CM, Huang CJ, Huang CY, Wu YY, Chang SF, Cheng WF,. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. Mol Cancer 2012; 11: 53.
39. Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, Tomlinson GE, Mastrangelo D, Pass HI, Brambilla E, Sathyanarayana UG, Czerniak B, Fujisawa T, Shimizu N, Gazdar AF,. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 2005; 113: 600-604.
40. Yu Y, Yin D, Hoque MO, Cao B, Jia Y, Yang Y, Guo M,. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol 2012; 33: 307-314.
41. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
42. Gao T, He B, Pan Y, Li R, Xu Y, Chen L, Nie Z, Gu L, Wang S,. The association of retinoic acid receptor beta2(RARbeta2) methylation status and prostate cancer risk: A systematic review and meta-analysis. PLoS ONE 2013; 8: e62950.
43. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D,. Quantitative RARbeta2 hypermethylation: A promising prostate cancer marker. Clin Cancer Res 2004; 10 (12 Pt 1): 4010-4014.
44. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castanos-Velez E, Blumenstein BA, Rosch T, Osborn N, Snover D, Day RW, Ransohoff DF, Steering PCS,. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63: 317-325.
45. Li Y, Song L, Gong Y, He B,. Detection of colorectal cancer by DNA methylation biomarker SEPT9: Past, present and future. Biomark Med 2014; 8: 755-769.
46. Gyparaki MT, Basdra EK, Papavassiliou AG,. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med 2013; 91: 1249-1256.
47. Meiers I, Shanks JH, Bostwick DG,. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: Review 2007. Pathology 2007; 39: 299-304.
48. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ,. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999; 18: 1313-1324.